A diverse group of cell-surface receptors, including many G protein-coupled receptors and receptor tyrosine kinases, activate phospholipase C (PLC) isozymes to hydrolyze phosphatidylinositol 4,5-bisphosphate into the second messengers diacylglycerol and 1,4,5-inositol trisphosphate. Consequently, PLCs control various cellular processes, and their aberrant regulation contributes to many diseases, including cancer, atherosclerosis, and rheumatoid arthritis. Despite the widespread importance of PLCs in human biology and disease, it has been impossible to directly monitor the real-time activation of these enzymes at membranes. To overcome this limitation, here we describe XY-69, a fluorogenic reporter that preferentially partitions into membranes and provides a selective tool for measuring the realtime activity of PLCs as either purified enzymes or in cellular lysates. Indeed, XY-69 faithfully reported the membrane-dependent activation of PLC-␤3 by G␣ q . Therefore, XY-69 can replace radioactive phosphatidylinositol 4,5-bisphosphate used in conventional PLC assays and will enable high-throughput screens to identify both orthosteric and allosteric PLC inhibitors. In the future, cell-permeable variants of XY-69 represent promising candidates for reporting the activation of PLCs in live cells with high spatiotemporal resolution.
Many extracellular stimuli, including various hormones, growth factors, and neurotransmitters initiate signaling cascades that result in the activation of phospholipase C (PLC) isozymes (1) (2) (3) . Active PLCs catalyze the conversion of the membrane-bound phospholipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ) 3 into two second messengers, inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol, which mobilize intracellular stores of Ca 2ϩ and activate protein kinase C isozymes, respectively. Furthermore, depletion of PIP 2 also alters the membrane association and/or activity of many proteins that harbor phosphoinositide-binding domains. Consequently, PLCs are key signaling proteins that regulate diverse cellular functions including proliferation, differentiation, migration, and nerve conductance (4) . Conversely, aberrant regulation of PLCs contributes to various diseases including cancer (5) (6) (7) , atherosclerosis (8) , and rheumatoid arthritis (9) .
The human genome encodes 13 PLCs grouped into six subfamilies (␤, ␦, ␥, ⑀, , and ). Most PLCs are autoinhibited by an X-Y linker that separates the X-and Y-boxes of the catalytic core (10) and mechanisms that release this autoinhibition are diverse and specific to the various subfamilies. For example, the PLC-␤ isozymes are directly activated by G␣ and G␤␥ subunits of heterotrimeric G proteins (11, 12) , whereas PLC-␥ isozymes are activated upon phosphorylation by tyrosine kinases (13) . Similarly, Rac1 activates certain PLC-␤ isozymes (14) as well as PLC-␥2 (14, 15) , but Rac1 binds to distinct regions of the two PLC subgroups. Therefore, to understand how PLCs are regulated to control normal cellular processes and physiology as well as disease states, it is crucial to have convenient assays of PLC activity that differentiate modes of regulations and that can be used in cells.
The canonical assay of the lipase activity of purified PLC isozymes uses radiolabeled PIP 2 as substrate. The enzymatic product, IP 3 , is then quantified by scintillation counting. However, this assay does not allow for continuous monitoring of PLC activity, and handling of radioactive materials requires special training and facilities. Likewise, cellular PLC activity is typically measured from the production of radiolabeled inositol phosphates after biosynthetic incorporation of radioactivity into phosphoinositide pools (16) . These assays are subject to cell-dependent differences in the steady-state metabolism of phosphoinositides and variable expression of PLCs. Alternatively, cell-permeable dyes that increase in fluorescence upon binding Ca 2ϩ are also routinely used to monitor PLC activity (17 cro ARTICLE the intracellular movement of fluorescently-tagged domains that bind specific lipid components, e.g. the GFP-tagged PH domain of PLC-␦1, which specifically interacts with PIP 2 , are also commonly used to monitor the activation of PLCs in live cells (18 -20) . However, like dyes that are indicators of Ca 2ϩ , these genetically-encoded biosensors do not directly measure the activity of PLCs and other lipid metabolizing enzymes can confound conclusions. In addition, the encoded biosensors have the potential to perturb cellular pathways to inadvertently modify cellular responses arising from external stimuli.
To address limitations with existing assays of PLCs, several PIP 2 derivatives have been developed to report the lipase activity of PLC isozymes (21) (22) (23) . However, the majority of these compounds are either inefficient substrates of PLCs or suffer from other drawbacks such as requiring a secondary enzymatic activity not related to PLCs. In contrast, we previously described the development of WH-15 (21) that converts into a highly fluorescent aminoquinoline upon hydrolysis by PLCs. PLCs hydrolyze WH-15 and PIP 2 with equal efficiency in mixed micelles. However, WH-15 is soluble and does not selectively partition into phospholipid membranes like PIP 2 , thereby limiting its utility to monitor PLCs at membranes as normally occurs in cells. For example, G␣ q and G␤␥ potently enhance the lipase activity of PLC-␤ isozymes at membranes, but this regulation was not observable using WH-15 (24) . Therefore, new biosensors are needed to report the real-time activation of membrane-resident PLCs. Here we describe a new fluorogenic substrate, XY-69, that readily partitions into membranes and that is specifically and efficiently hydrolyzed by mammalian PLCs to produce a robust fluorescent signal suitable for monitoring membrane-resident PLCs. Further modifications of XY-69 will allow PLCs to be monitored in cells with high spatiotemporal resolution.
Results and discussion

Design and synthesis of XY-69
We developed XY-69 to robustly monitor PLC activity at membranes (Fig. 1A) . The design of XY-69 relies on the fact that the 6-hydroxyl position of PIP 2 remains solvent exposed within the active site of PLCs, such that modifications at this site minimally compromise the capacity of PIP 2 derivatives to function as PLC substrates (25) . Therefore, to create XY-69, fluorescein was introduced at the sn-1 position of PIP 2 , whereas 4-(dimethylaminoazo)benzene-4-carboxylic acid (DABCYL) was introduced at the 6-hydroxyl position. This arrangement is expected to effectively quench the intrinsic fluorescence of fluorescein by the DABCYL moiety. However, once XY-69 is cleaved by PLCs, the fluorophore/quencher pair will be separated resulting in a dramatic increase in the quantum yield of the fluorescein group. XY-69 was also designed to retain a long alkyl chain (C 15 H 31 ) at the sn-2 position to favor the partitioning of XY-69 into lipid membranes. Therefore, much like diacylglycerol, the fluorescent product of XY-69 hydrolysis is expected to remain in lipid membranes.
The synthesis of XY-69 ( Fig. 2 ) started with the inositol intermediate 3 that we previously developed (25) . Olefin metathesis of 3 with the terminal alkene N-tert-butoxycarbonyl-2allyloxyethanolamine 4 in the presence of Hoveyda-Grubbs catalyst followed by hydrogenation produced 5. The 4-and 5-hydroxyl groups in 5 were phosphorylated through reactions with dibenzyl diisopropylphosphoramidite followed by oxidation with meta-chloroperoxybenzoic acid (mCPBA). The resulting phosphate ester was treated with tetrabutylammonium fluoride (TBAF) to remove the tert-butyldiphenylsilyl (TBDPS) protective group. Phosphorylation of 6 with compound 7, which was prepared according to literature protocols A membrane-associated fluorogenic PLC reporter (26) , followed by oxidation by t-BuOOH, generated the coupled intermediate 8 in 85% yield. Removal of the benzyloxycarbonyl (Cbz) protective group through hydrogenolysis provided the corresponding primary amine, which was subsequently acylated with the fluorescein derivative 9. The resulting compound was treated with trimethylsilyl bromide (TMSBr) to remove the methoxymethyl (MOM) and benzyl (Bn) protective groups. The tert-butoxycarbonyl (Boc) protective group was also removed during this process to produce 10, which was subsequently reacted with 11 to generate XY-69 in 80% yield.
XY-69 is a PLC-selective reporter
XY-69 was initially incubated with purified PLC-␦1 at 37°C for 1 h and the fluorescence excitation and emission spectra of the reaction mixture were recorded ( Fig. 1B ). Excitation and emission maxima were 490 and 518 nm, respectively. These maxima are similar to the equivalent numbers for isolated fluorescein (490 and 525 nm). Liquid chromatography-mass spectrometry (LC-MS) analysis of the assay mixture was also carried out and confirmed the formation of the expected product 1 (Fig. S1 ). In subsequent experiments, cleavage of XY-69 was detected at 520 nm after excitation at 485 nm.
PLCs require a Ca 2ϩ cofactor to stabilize the transition state during the hydrolysis of PIP 2 (27, 28) . We thus investigated the effect of Ca 2ϩ concentration on XY-69 hydrolysis (Fig. 1C ). As expected, increasing the concentration of free Ca 2ϩ led to increased rates of hydrolysis of XY-69 by PLC-␦1 and this behavior mirrored earlier work with WH-15 (24) . Conversely, without free Ca 2ϩ , there was essentially no hydrolysis of XY-69. Consequently, amounts of free Ca 2ϩ were tightly controlled throughout this work to ensure efficient enzymatic reactions. To demonstrate that XY-69 can be used to monitor PLC activity, the real-time fluorescence of detergent-solubilized XY-69 incubated with purified PLC-␦1 was recorded ( Fig. 3A) . Purified PLC-␦1 harboring a single mutation (E341A) within its active site has undetectable lipase activity (29) and was used in a parallel reaction. XY-69 generated approximately a 20-fold increase in fluorescence with PLC-␦1 relative to an identically treated sample containing PLC-␦1 (E341A). These results strongly suggest that the fluorescence increase arises from the enzymatic action of PLC-␦1 on XY-69.
To further test whether XY-69 functions as a substrate for other PLC isoforms, the reporter was incubated with either purified PLC-␤3 or -␥1 in reactions analogous to that described for PLC-␦1. As shown in Fig. 3A , XY-69 is hydrolyzed with similar kinetics by each of the PLC isozymes. The catalytic domains of PLC isozymes are highly conserved (30) and consequently, XY-69 is likely a general PLC substrate.
We also tested whether other lipid-metabolizing enzymes that utilize PIP 2 as a substrate could generate fluorescent signals from XY-69. For these tests, we also produced XY-23 ( Fig.  3B ), which contains a fluorescein moiety but not the DABCYL quencher of XY-69. Consequently, XY-23 is intrinsically fluorescent and enzymatic transformations of XY-23 should invariably generate new fluorescent products. In this respect, XY-23 is highly similar to PIP 2 and is expected to be a substrate for isozymes of phospholipase D (PLD), phospholipase A (PLA), and phosphoinositide 3-kinase (PI3K), as well as PLCs (31) . Both XY-23 and XY-69 were subjected to enzymatic reactions with PLCs (-␦1, -␥1, and -␤3), PLD1, PLA2, and PI3K␣. The reaction mixtures were then separated by thin layer chromatography (TLC) and visualized by fluorescence. As shown in Fig. 3C , for XY-23, each lipid-metabolizing enzyme produced a new fluorescent product. In contrast, only the PLCs were capable of hydrolyzing XY-69, attesting to the PLC-selective nature of this fluorogenic reporter. 
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To assess potential nonspecific cleavage of XY-69 by the entire repertoire of cellular phosphodiesterases, the stability of XY-69 was evaluated in lysates derived from HEK293 cells ( Fig.  4 ). Cells transfected with plasmid encoding wildtype PLC-␤3, the catalytically inactive mutant PLC-␤3 (H323A), constitutively active PLC-␤3 (⌬XY) lacking the autoinhibitory XY linker, or the parent vector were lysed 24 h after transfection; the resulting lysates were normalized for total protein and tested for capacity to hydrolyze XY-69 ( Fig. 4) .
Importantly, lysates from cells transfected with either the parent vector or vector encoding catalytically inactive PLC-␤3 (H323A) exhibited the minimal capacity to hydrolyze XY-69 as evidenced by minimal increases in fluorescence. In contrast, XY-69 was efficiently hydrolyzed by lysate containing wildtype PLC-␤3 and this rate increased further for lysate containing constitutively active PLC-␤3 (⌬XY). These results confirm: (i) the expected low basal activities of PLCs prior to upstream stimulation; (ii) the lack of nonspecific hydrolysis of XY-69 by the cellular milieu; and (iii) the capacity of XY-69 to monitor the intrinsic regulation of PLCs. Taken together, these results unequivocally demonstrate that XY-69 is a sensitive and selective reporter of the lipase activity of PLCs in complex cell lysates. The fact that the fluorescence window is as large as 20-fold highlights the potential application of XY-69 in quantifying PLC activity in different cell lines.
Membrane association and G␣ q activation of XY-69
PIP 2 is a membrane-associated phospholipid and PLCs catalyze the hydrolysis of PIP 2 at the lipid-aqueous interface. Therefore, XY-69 was assessed for capacity to incorporate into membranes used to assay PLC activity. We originally attempted to use a variety of polybasic carriers including histones (32) and polyamines (32) and liposomes (33) to deliver XY-69 or XY-23 into cells with the expectation that these PIP 2 analogs would partition into cellular membranes. However, results were inconsistent with low efficiencies of delivery and high sequestration into endosomal compartments. Instead, we used an in vitro membrane association assay originally developed to measure protein-lipid interactions. In this format, liposomes incubated with either XY-69 or WH-15 were recovered after centrifugation in a sucrose gradient (Fig. 5A) . Quantification of the top (lipid) and bottom sucrose layers (Fig. 5B ) indicated that ϳ90% of XY-69 incorporated into the lipid fraction. In contrast, WH-15 preferentially (ϳ60%) partitioned into the aqueous fraction. Therefore, XY-69 efficiently partitions into lipid vesicles that mimic cellular membranes.
XY-69 was subsequently reconstituted into lipid vesicles and used to monitor the phospholipase activities of purified PLCs (Fig. 6A ). Under these conditions, XY-69 was hydrolyzed with similar kinetics by PLC-␦1, -␤3, and -␥1. In contrast, catalytically inactive PLC-␦1 (E341A) was unable to hydrolyze XY-69.
We previously showed that the soluble, fluorogenic substrate WH-15 cannot be used to monitor the activation of PLC-␤ HEK293 cells were transfected with plasmids encoding the indicated forms of PLC-␤3 or the corresponding parent vector and lysed after 24 h. The resulting lysates were normalized for total protein before addition of XY-69 and monitored for fluorescence ( ex/em ϭ 485/520 nm). Expression of PLC-␤3 constructs was verified by Western blot (inset). Plots were representatives of two independent experiments. Each experiment was run in triplicates with error bars as standard deviations.
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isozymes by membrane-resident G␣ q (24) . In contrast, XY-69 reconstituted into lipid vesicles with G␣ q readily reports this activation (Fig. 6B) . G␣ q increased the initial rate of XY-69 hydrolysis by PLC-␤3 ϳ12-fold, consistent with measurements when [ 3 H]PIP 2 was used as the substrate (Fig. 6C ). For comparison, PLC-␤3 (PH-C2), which is not responsive to G␣ q in conventional assays (24) , is also unresponsive to G␣ q in this assay.
Finally, to demonstrate that XY-69 has the capacity to report activity of endogenous PLCs, HEK293 cells transfected with plasmid encoding G␣ q (Q209L) or the parent vector were lysed 48 h after transfection with assay buffer containing XY-69. As expected, cells transfected with the parent vector showed essentially no increase in fluorescence associated with the hydrolysis of XY-69 ( Fig. 7, A and B) . In contrast, cells transfected with G␣ q (Q209L) showed an approximate 10-fold increase in fluorescence related to the robust hydrolysis of XY-69 ( Fig. 7, A  and B) . These results are consistent with the equivalent comparison using conventional labeling of cells with [ 3 H]inositol followed by radioactivity counting of [ 3 H]inositol phosphates produced by PLCs (Fig. 7C ). Taken together, these results demonstrate that XY-69 successfully mimics PIP 2 to report the regulation of PLCs operating at membranes. Consequently, XY-69 is able to replace [ 3 H]PIP 2 used in conventional assays used to measure the phospholipase activity of PLCs.
In summary, we have developed a membrane-bound fluorogenic reporter, XY-69, that monitors the lipase activity of PLC isozymes in real-time with high sensitivity. The reporter works with both detergent micelles and lipid vesicles and can be used with either purified PLCs or cellular lysates. Furthermore, XY-69 captures the activation of PLC activity through intrinsic regulation or activation by G␣ q , which requires the presence of membranes. Consequently, XY-69 is suitable to replace radioactive PIP 2 that is used in the canonical enzymatic assay of PLC activity, with the advantages of continuous monitoring, highthroughput and avoidance of using radioactive materials. These features enable XY-69 to be used for development of isozymeselective inhibitors of PLCs. Given the general significance of PLC isozymes, isozyme-selective inhibitors will likely find applications as novel chemical probes or therapeutics for PLCassociated diseases. Finally, other derivatives of phosphoinositides such as PIP 3 and PI3P have been delivered into cells through caging negatively charged phosphates to produce the corresponding charge-neutral esters (34, 35) . Accordingly, when a suitable delivery method is available, XY-69 could be used to monitor PLC activity in live cells with high spatiotemporal resolution.
Experimental procedures
PLC assay in detergent micelles
In a PerkinElmer ProxiPlate TM -384 Plus F black plate, XY-69 was added to a final concentration of 5 M in assay buffer containing HEPES (50 mM, pH 7.4), KCl (70 mM), CaCl 2 (3 mM), EGTA (3 mM), DTT (2 mM), cholate (0.5%), and fatty acid-free BSA (0.2 mg/ml). The free Ca 2ϩ concentration in this buffer is calculated as 18.9 M according to the Ca-EGTA Calculator v1.3 program using constants from Theo Schoenmakers' chelator (36) . The PLC-␦1 (25 ng), PLC-␦1 (E341A) (25 ng), PLC-␥1 (100 pg), or PLC-␤3 (50 ng) enzymes in the same buffer were then added to initiate enzymatic reaction at 37°C. The final volume of the assay was 10 l. The progression of the assay was monitored continuously by fluorescence intensity of the reaction mixture on a PerkinElmer Wallac EnVision 2103 multilabel reader with an excitation wavelength of 485 nm (bandwidth of 10 nm) and an emission wavelength of 520 nm (bandwidth of 10 nm).
When cell lysates were used in this assay, HEK293 cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) containing fetal bovine serum (10%), penicillin (100 units/ml), and streptomycin (100 g/ml) at 37°C. Cells were plated in a 12-well dish at a density of 60,000 cells/ well in DMEM and 24 h after plating were transfected with the indicated DNA at 300 ng/well using Continuum (Gemini Bio-Sciences). Forty-eight hours post-transfection, cells were washed with PBS, and lysed with RIPA buffer containing NaCl (150 mM), Nonidet P-40 (1%), SDS (0.1%), Tris-HCl (50 mM, pH 8), and sodium deoxycholate (12 mM). Western blotting was performed to confirm the expression of PLC-␤3 using anti-PLC ␤3 (Santa Cruz Biotechnology). Lysates were normalized for total protein concentration prior to use in the reporter assay as described above. 
A membrane-associated fluorogenic PLC reporter PLC assay in lipid vesicles
Lipid vesicles containing liver phosphatidylethanolamine (PE, 330 M), brain PIP 2 (30 M), and XY-69 (7.5 M) were generated by mixing the lipids, drying the mixture under a stream of nitrogen, and re-suspending the dried lipid mixture in HEPES (20 mM, pH 7.4) using a probe sonicator. In parallel, PLC isozymes were diluted to the desired concentration with a buffer containing HEPES (20 mM, pH 7.4), NaCl (50 mM), dithiothreitol (DTT, 2 mM), and fatty acid-free BSA (1 mg/ml). To a PerkinElmer ProxiPlate TM -384 Plus F black plate was added 6ϫ buffer (2 l) containing HEPES (80 mM, pH 7.4), KCl (420 mM), DTT (10 mM), EGTA (18 mM), and CaCl 2 (14.1 mM). Lipid vesicle (8 l) was then added, followed by addition of PLC protein (2 l) at concentrations of 11.4, 18.9, 67.3, and 66.6 nM for PLC-␦1, -␦1 (E341A), -␥1, and -␤3, respectively, to initiate the assay. The assay was incubated at 37°C and fluorescence was recorded as described above.
G␣ q activation of PLC-␤3
Lipid vesicles containing liver PE (500 M), brain PIP 2 (50 M), and XY-69 (10 M) were generated by drying the lipids under a stream of nitrogen and re-suspending the resulting mixture in HEPES (20 mM, pH 7.4) using a probe sonicator. Wildtype PLC-␤3 and PLC-␤3 (PH-C2) were diluted with 2ϫ assay buffer containing HEPES (20 mM, pH 7.4), KCl (40 mM), NaCl (30 mM), EGTA (6 mM), AlCl 3 (60 M), MgCl 2 (5 mM), DTT (4 mM), CaCl 2 (3 mM), NaF (20 mM), and 0.3 mg/ml of fatty acid-free BSA) to final concentrations of 10 and 20 nM, respectively. G␣ q was then diluted with the same 2ϫ assay buffer to the final concentration of 480 nM. To a PerkinElmer Proxi-Plate TM -384 Plus F black plate was added 2 l of PLC solution and 4 l of G␣ q solution, followed by the addition of 6 l of lipids to initiate the reaction. The assay was incubated at room temperature and fluorescence was recorded as described above.
Measurement of activity of endogenous PLCs
HEK293 cells were plated in 6-well tissue culture plates at the density of 150,000 cells/well in DMEM supplemented with 10% fetal bovine serum and incubated overnight in a humidified, 37°C, 5% CO 2 incubator. Cells were transfected with 300 ng of pcHA-lic control vector or 30 ng of pcHA GNAQ Q209L DNA plus 270 ng of pcHA-lic control using Continuum transfection reagent (Gemini Bio Products). After 48 h, the medium was removed and replaced with 400 l of inositol-free DMEM. The cells were cultured for another 24 h and then washed with icecold PBS before being collected with PBS. The suspension was briefly spun to pellet, the supernatant was removed, and the resulting pellets were snap-frozen with liquid N 2 and stored at Ϫ80°C for subsequent uses.
The cell pellets from two wells were combined in a microcentrifuge tube on ice by resuspending cells with 80 l of lipid vesicles containing liver PE (500 M), brain PIP 2 (50 M), and XY-69 (10 M) in HEPES (20 mM, pH 7.4) and 80 l of 2ϫ assay buffer containing HEPES (20 mM, pH 7.4), KCl (40 mM), NaCl (30 mM), MgCl 2 (5 mM), AlCl 3 (0.06 mM), NaF (20 mM), DTT (4 mM), EGTA (6 mM), CaCl 2 (3 mM), and 0.3 mg/ml of fatty acidfree BSA. The cells were lysed by passing through a syringe with a 27-gauge hypodermic needle 10 times. The resulting mixture 
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was then incubated at 37°C. At an indicated time point, 30 l of mixture was taken out and centrifuged for 40 s, and 10 l of supernatant was transferred to a PerkinElmer ProxiPlate TM -384 Plus F black plate for fluorescence measurement as described above. The activity of endogenous PLCs was calculated from the fluorescence increase as the slope. For comparison, the endogenous PLC activity was also measured by labeling cells with 1 Ci of myo-[ 3 H]inositol (PerkinElmer) and quantifying [ 3 H]inositol phosphates as previously described.
TLC analysis of assay mixtures
XY-69 or XY-23 was added to various assay buffers (30 l) to reach a final concentration of 67 M. The components for assay buffers included: 1) HEPES (50 mM, pH 7.4), KCl (70 mM), CaCl 2 (3 mM), EGTA (3 mM), DTT (2 mM), cholate (0.5%), and fatty acid-free BSA (0.2 mg/ml) for PLCs; 2) Tris-HCl (12.5 mM, pH 8.0), SDS (6.2 mM), and EtOH (0.1%) for PLD1; 3) Tris-HCl (50 mM, pH 7.5), KCl (150 mM), and CaCl 2 (10 mM) for PLA2; and 4) MOPS (50 mM, pH 6.5), NaCl (100 mM), sodium cholate (0.5 mM), DTT (1 mM), MgCl 2 (10 mM), and ATP (2 mM) for PI3K␣. The enzymes PLC-␦1 (25 ng), PLC-␦1 (E341A) (25 ng), PLC-␥1 (100 pg), PLC-␤3 (50 ng), PLD1 (40 units), PLA2 (2 units), or PI3K␣ (15 ng) were then added to the initial enzymatic reactions. The assay mixtures were incubated at 37°C for 1 h, and samples (1 l) were taken out and spotted on TLC plates (Merck, Silica Gel-60 
Membrane association assay
The liposome mixture was prepared from stock solutions of lipids in CHCl 3 for a final composition of 45% phosphatidylcholine, 25% PE, 15% cholesterol, 10% phosphatidylinositol, and 5% phosphatidylserine. The solvent was blown off under a stream of nitrogen followed by drying under vacuum for at least 1 h. The lipid film was then suspended in buffer composed of MOPS (50 mM, pH 6.7), NaCl (100 mM), DTT (1 mM), and MgCl 2 (10 mM) to a concentration of 2 mM. Liposomes were extruded through a 0.03-m pore size polycarbonate filter membrane at least 11 times back and forth. XY-69 (10 M) or WH-15 (10 M) and liposomes (1 mM) were incubated in buffer at room temperature for 5 min in a total volume of 150 l. The suspension was adjusted to 30% sucrose by the addition of 100 l of 75% (w/v) sucrose in buffer followed by mixing. Buffer (200 l) containing 25% (w/v) sucrose was then overlaid on the high-sucrose suspension followed by 50 l of buffer containing no sucrose. The sample was centrifuged at 55,000 rpm in a Beckman swinging-bucket rotor (TLS 55) for 1 h at 4°C. The bottom 350 l and top 150 l were manually collected using a syringe and adjusted to the same volume (350 l). Each fraction was then diluted with 1ϫ PLC buffer containing HEPES (50 mM, pH 7.4), KCl (70 mM), CaCl 2 (3 mM), EGTA (3 mM), DTT (2 mM), and cholate (0.5%). Fractions containing XY-69 were diluted 1:50, whereas WH-15 fractions were diluted 1:3. PLC-␦1 was diluted to 10 ng/l in 1ϫ PLC buffer with 1 mg/ml of fatty acid-free BSA. In a PerkinElmer ProxiPlate TM -384 Plus F black plate, 5 l of the above reporter solution was mixed with 5 l of PLC-␦1 or PLC dilution buffer. After incubation at room temperature for 6 h, fluorescence intensity was measured on a PerkinElmer Wallac EnVision 2103 multilabel reader as described before. The fluorescence intensity of the samples treated with PLC were subtracted with that of the samples treated with PLC dilution buffer. The fluorescence intensity differences were used to calculate the amount of XY-69 or WH-15, which was then used to calculate the reporter distribution. Figure 7 . Measurement of endogenous PLC activity with XY-69. HEK293 cells were grown in 6-well culture plates at the density of 150,000 cells/well and transfected with either pcHA-GNAQ (Q209L) (30 ng) ϩ pcHA-lic (270 ng) or the control pcHA-lic vector (300 ng) alone. A, after 48 h, the cell pellets were collected and used for hydrolysis of XY-69 (5 M). The reaction progression was monitored by fluorescence ( ex / em ϭ 485/520 nm). Plots are representatives of three independent experiments. Each experiment was run in triplicates with error bars as standard deviations. B, the fluorescence increase at t ϭ 12 min in panel A was calculated and plotted. C, after 24 h, the medium was replaced with inositol-free DMEM and myo-[ 3 H]inositol (1 Ci) was subsequently added. The cells were cultured for another 12 h, treated with LiCl (10 mM) for 1 h, and [ 3 H]inositol phosphates were then isolated and quantified. Data are representatives of three independent experiments. Each data point is an average of two replicates in one independent experiment.
